New Japanese encephalitis vaccines: alternatives to production in mouse brain.
about
Mechanism and significance of cell type-dependent neutralization of flavivirusesFeasibility of cross-protective vaccination against flaviviruses of the Japanese encephalitis serocomplexResearch and development of Zika virus vaccines.Japanese encephalitis: the virus and vaccinesThe Potential Use of Wolbachia-Based Mosquito Biocontrol Strategies for Japanese EncephalitisProspects for a Zika Virus Vaccine.Flaviviruses, an expanding threat in public health: focus on dengue, West Nile, and Japanese encephalitis virus.Development of replication-competent viral vectors for HIV vaccine delivery.Japanese encephalitis virus vaccine candidates generated by chimerization with dengue virus type 4Generation and characterization of a new mammalian cell line continuously expressing virus-like particles of Japanese encephalitis virus for a subunit vaccine candidateA molecularly cloned, live-attenuated japanese encephalitis vaccine SA14-14-2 virus: a conserved single amino acid in the ij Hairpin of the Viral E glycoprotein determines neurovirulence in miceDynamics of Japanese encephalitis virus transmission among pigs in Northwest Bangladesh and the potential impact of pig vaccination.Partially neutralizing potency against emerging genotype I virus among children received formalin-inactivated Japanese encephalitis virus vaccine.Japanese Encephalitis VaccinesDNA prime/Adenovirus boost malaria vaccine encoding P. falciparum CSP and AMA1 induces sterile protection associated with cell-mediated immunity.Safety and immunogenicity of a freeze-dried, Vero cell culture-derived, inactivated Japanese encephalitis vaccine (KD-287, ENCEVAC®) versus a mouse brain-derived inactivated Japanese encephalitis vaccine in children: a phase III, multicenter, doubleImmune response to live-attenuated Japanese encephalitis vaccine (JE-CV) neutralizes Japanese encephalitis virus isolates from south-east Asia and India.Genetic and phenotypic properties of vero cell-adapted Japanese encephalitis virus SA14-14-2 vaccine strain variants and a recombinant clone, which demonstrates attenuation and immunogenicity in mice.Profiling of viral proteins expressed from the genomic RNA of Japanese encephalitis virus using a panel of 15 region-specific polyclonal rabbit antisera: implications for viral gene expression.Immunogenicity and safety of currently available Japanese encephalitis vaccines: a systematic reviewGenetic Determinants of Japanese Encephalitis Virus Vaccine Strain SA14-14-2 That Govern Attenuation of Virulence in MiceA Lentiviral Vector Expressing Japanese Encephalitis Virus-like Particles Elicits Broad Neutralizing Antibody Response in Pigs.Formalin Inactivation of Japanese Encephalitis Virus Vaccine Alters the Antigenicity and Immunogenicity of a Neutralization Epitope in Envelope Protein Domain III.The involvement of microglial cells in Japanese encephalitis infections.Construction and immune efficacy of recombinant pseudorabies virus expressing PrM-E proteins of Japanese encephalitis virus genotype І.Development and characterization of the replicon system of Japanese encephalitis live vaccine virus SA14-14-2.Molecular and immunological characterization of a DNA-launched yellow fever virus 17D infectious clone.JE-ADVAX vaccine protection against Japanese encephalitis virus mediated by memory B cells in the absence of CD8(+) T cells and pre-exposure neutralizing antibodyRational design of a flavivirus vaccine by abolishing viral RNA 2'-O methylation.A game of numbers: the stoichiometry of antibody-mediated neutralization of flavivirus infection.A chimeric dengue virus vaccine using Japanese encephalitis virus vaccine strain SA14-14-2 as backbone is immunogenic and protective against either parental virus in mice and nonhuman primates.Zoonotic encephalitides caused by arboviruses: transmission and epidemiology of alphaviruses and flaviviruses.Memory immune response and safety of a booster dose of Japanese encephalitis chimeric virus vaccine (JE-CV) in JE-CV-primed childrenHuman adenovirus 5-vectored Plasmodium falciparum NMRC-M3V-Ad-PfCA vaccine encoding CSP and AMA1 is safe, well-tolerated and immunogenic but does not protect against controlled human malaria infection.Phase III clinical trials comparing the immunogenicity and safety of the vero cell-derived Japanese encephalitis vaccine Encevac with those of mouse brain-derived vaccine by using the Beijing-1 strain.Advances in Non-Viral DNA Vectors for Gene Therapy.Zika Virus: Immunity and Vaccine Development.Epidemiological Features of Japanese Encephalitis in Taiwan from 2000 to 2014.Biological and genetic properties of SA₁₄-14-2, a live-attenuated Japanese encephalitis vaccine that is currently available for humans.DNA-launched live-attenuated vaccines for biodefense applications.
P2860
Q23032973-B052AA27-80F6-4C9E-9BBB-60DE92F5EC35Q24737461-126DB933-1E23-4081-8A7E-B970E7943036Q26252115-3357A844-B88E-4B22-B04F-EEA94B3CBB01Q27010434-72D32C80-EBB1-474E-A2FE-9CE76F2780A6Q28084923-3D160F7B-A304-428D-AA7C-4A17D52E46E1Q30235612-41073905-DCF7-4044-BC21-BEB5BD205536Q30857727-216E486D-A494-4DC2-8733-7B02ACB666DDQ33694226-EDE1DEB9-9F5B-4536-8CB0-3B3DDCFAB230Q33852635-DB6BF3A3-3FE8-43E3-B61D-4D9F63BBE366Q33891505-A21D3D3E-A861-424D-99D1-EFC0ACD5318FQ33982616-C2F8FD40-75D4-467F-988A-A3F07B7C2CC5Q34257111-3D5203DE-2D01-46A2-862B-B3519B7929B6Q34431587-5EFA2A37-A7B9-4986-92C8-5A5AF069372FQ34466587-3606205B-9B0F-43E6-A68F-901A228E9FF4Q34606356-A9599E02-59EE-4221-B098-8D77FC98AE40Q34976644-785D3259-EDBD-41EB-80FC-E7F980C919DEQ35127585-50EA8E01-A259-47C6-A8B5-09D72B7A6973Q35140658-59A7D410-82E1-441B-A635-6D7BDA5AD441Q35542073-06BBA3EF-8D0C-45AF-8890-B209CF254CACQ35558900-5928EE22-2BA8-40DC-BE3E-74CC8A98C4FCQ35760499-EB92ABF8-B1B1-45DE-BCD9-D6CE668B58D8Q35799379-9293B967-73F8-4E2C-B4EA-186AE9A8FB7FQ35818688-1EED7A2D-0DEB-4B3F-94A1-C1DC0624286EQ36167789-9DB6878F-DE88-4D7B-9F62-E1F954B3C33AQ36364196-58F343F1-E1FA-49E0-8D97-599F1FD46F90Q36718676-E17A540C-8E20-474A-9890-6F7F7A9FA927Q36739363-13A65DBD-2E57-4F61-90B6-666CA2C24CA3Q36760059-4CA34714-CC40-432A-B1C7-2CF200C64A46Q36827340-BCF8B1B3-3598-4A81-959B-F4F10447CAAEQ37012203-ECEABA07-3209-40B4-85A3-B2A6F89B4153Q37336762-23A602B8-0E42-4C43-A0BF-26FB8826F23AQ37473538-FFCE14B8-C4EC-4989-9AC8-895BCF7E67D4Q37521922-FB54C879-1DD4-4810-B621-63366121B7B8Q37530505-4AF4B4D2-1720-4E43-9930-EE7CFE06209BQ37544985-A5CA021D-213E-47D2-AE00-58CE8F3D8C2FQ37676243-F00D841B-46C7-4B14-9A68-EFA29802D831Q38969772-CBE9E90F-445D-45FF-A9E5-1097936F38C5Q39207467-E3F52B2F-5D4D-4CEF-981C-0C676F47E9F9Q39290828-C8334E2E-734E-4CB8-8FAD-D79C5A09B3D8Q40110791-361FA01B-7983-411B-AA1A-E17804442EEE
P2860
New Japanese encephalitis vaccines: alternatives to production in mouse brain.
description
2011 nî lūn-bûn
@nan
2011 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի մարտին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
New Japanese encephalitis vaccines: alternatives to production in mouse brain.
@ast
New Japanese encephalitis vaccines: alternatives to production in mouse brain.
@en
New Japanese encephalitis vaccines: alternatives to production in mouse brain.
@nl
type
label
New Japanese encephalitis vaccines: alternatives to production in mouse brain.
@ast
New Japanese encephalitis vaccines: alternatives to production in mouse brain.
@en
New Japanese encephalitis vaccines: alternatives to production in mouse brain.
@nl
prefLabel
New Japanese encephalitis vaccines: alternatives to production in mouse brain.
@ast
New Japanese encephalitis vaccines: alternatives to production in mouse brain.
@en
New Japanese encephalitis vaccines: alternatives to production in mouse brain.
@nl
P2860
P356
P1476
New Japanese encephalitis vaccines: alternatives to production in mouse brain.
@en
P2093
Scott B Halstead
Stephen J Thomas
P2860
P304
P356
10.1586/ERV.11.7
P577
2011-03-01T00:00:00Z